Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Effect of Romidepsin treatment on patient-derived liver cancer cells

ABSTRACT: Effect of Romidepsin treatment on patient-derived liver cancer cells

PROVIDER: PRJNA946751 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR23920346_1.fastq.gz	Fastqsanger.gz
	SRR23920346_2.fastq.gz	Fastqsanger.gz
	SRR23920347_1.fastq.gz	Fastqsanger.gz
	SRR23920347_2.fastq.gz	Fastqsanger.gz
	SRR23920348_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 24

Similar Datasets

Effect of Romidepsin treatment on patient-derived liver cancer cells

Project description:Romidepsin displayed potent antitumor activity in our lenvatinib-resistant PDCs, we wanted to investigate the underlying mechanism of how romidepsin initiated susceptibility to conquer lenvatinib resistance in liver cancer.

2024-03-17 | GSE227751 | GEO

Romidepsin and afatinib combination treatment induce synergistic anti-lymphoma effect in CTCL

Project description:Cutaneous T-cell lymphomas (CTCL) are an aggressive group of T-cell lymphomas that present in the skin and are associated with dismal prognosis. Romidepsin is a histone deacetylase (HDAC) inhibitor that is an FDA approved systemic therapeutic indicated for the treatment of CTCL in patients who have received at least one prior systemic therapy. Romidepsin demonstrates promising single agent activity in patients with advanced stages of CTCL, however response is typically low and not durable. One method of overcoming resistance to romidepsin and improving response is through combination therapies. Here, we demonstrate that romidepsin in combination with the epidermal growth factor receptor (EGFR) inhibitor afatinib and afatinib dimaleate produce strongly synergistic anti-tumor effects in CTCL cell lines and an in vivo model of CTCL. Gene expression and western blot analysis further identifies the decreased activation of the JAK-STAT signalling pathway as a key driver of synergy in this combination. These results suggest a potential indication for FDA-approved EGFR inhibitors previously unrecognized in CTCLs as a combination therapeutic with HDAC inhibitors that can be rapidly adopted in the clinic.

2024-07-12 | GSE237167 | GEO

Quantitative RNAseq Analysis of Treatment Outcomes with Talazoparib, Romidepsin or Combination in MBL2 cell line

Project description:To explore the molecular mechanisms by which romidepsin potentiates the effect of talazoparib, RNA sequencing analysis of MBL2 cell lines treated with talazoparib, romidepsin, or talazoparib plus romidepsin was performed. 40% of the 2023 genes in combination were from talazoparib, whereas only 5.9% of the genes deregulated during the treatment with the combination of talazoparib plus romidepsin were from the effect of romidepsin. 94 genes were presented in all three treatment groups and included upregulation of Prdm1, Dusp5, and CD74, among others. Analysis of genes responsible for DNA repair, cell cycle arrest and apoptosis demonstrated the contribution of romidepsin to downregulation of DNA repair, the synergistic effect of romidepsin and talazoparib on downregulation of genes of cell cycle leading to cell cycle arrest, and activation of apoptosis by talazoparib predominantly.

2020-09-04 | GSE157434 | GEO

Patient-Derived Liver on Chips

Project description:Patient-Derived Liver on Chips

| PRJNA779387 | ENA

Nascent RNA sequencing (PRO-seq) after 200nM romidepsin treatment of H9 cells

Project description:Nascent RNA sequencing (PRO-seq) after 200nM romidepsin treatment of H9 cells

2019-12-12 | GSE141843 | GEO

Romidepsin and afatinib combination treatment induce synergistic anti-lymphoma effect in CTCL

Project description:Romidepsin and afatinib combination treatment induce synergistic anti-lymphoma effect in CTCL

| PRJNA994103 | ENA

Romidepsin and azacitidine synergize in their epigenetic modulatory effects to induce apoptosis in CTCL

Project description:We demonstrate that the combination of the HDAC inhibitor, romidepsin, and the demethylating agent, azacitidine, exerts synergistic anti-proliferative effects and induction of apoptosis involving activation of the caspase cascade in CTCL cell lines as well as CD4+ T cells derived from patients with SÃ©zary Syndrome (SS) with high tumor burden. We identified genes that were selectively induced by the combination treatment, such the tumor suppressor gene RhoB. We performed global CpG methylation-sequencing in a CTCL cell line and in patient cells. Results showed a subset of genes with a unique change in methylation profile in the combination treatment as compared to single drugs.

2016-03-30 | E-GEOD-66732 | biostudies-arrayexpress

Effect of CLDN1 mAb on primary patient derived liver organoids

Project description:Effect of CLDN1 mAb on primary patient derived liver organoids

| PRJNA851416 | ENA

RNA sequencing of BM-derived senescent MDSCs treated or not with Romidepsin

Project description:RNA sequencing of BM-derived senescent MDSCs treated or not with Romidepsin

2023-03-02 | GSE199921 | GEO

Expression data of Panc1 cells treated with romidepsin and tamoxifen

Project description:Tamoxifen enhances romidepsin-induced senescence in pancreatic cancer cells. We compared gene-expression profile among untreated control, romidepsin-treated, tamoxifen-treated, and romidepsin plus tamoxifen-treated Panc1 cells.

2021-08-21 | GSE182526 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data